Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
84 hedge funds and large institutions have $316M invested in Avadel Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 30 increasing their positions, 18 reducing their positions, and 13 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 18
31% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 13
6% more capital invested
Capital invested by funds: $299M → $316M (+$16.8M)
4.99% more ownership
Funds ownership: 65.64% → 70.63% (+5%)
4% more funds holding
Funds holding: 81 → 84 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $981K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$20.3M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$12.2M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$3.73M |
| 4 |
AC
Armistice Capital
New York
|
+$3.71M |
| 5 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$2.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$20.5M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$4.4M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4M |
| 4 |
JP Morgan Chase
New York
|
-$3.38M |
| 5 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
-$1.48M |
AVDL Hedge Fund Activity: Q2 2016 in Review
84 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2016, worth a combined $316M — up 5.6% from $299M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new AVDL positions and 13 closed out — a net gain of 4 holders — while 30 added to existing stakes and 18 trimmed.
The largest buyer was Janus Henderson Investors US, adding an estimated $20.3M. The largest seller was Bank of New York Mellon, cutting an estimated $20.5M.
- 84 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2016, up from 81 in Q1 2016.
- Funds reported $316M of Avadel Pharmaceuticals stock for Q2 2016, up 5.6% quarter-over-quarter.
- 17 funds opened new Avadel Pharmaceuticals positions in Q2 2016 and 13 closed out, a net change of +4 holders.
- The largest Avadel Pharmaceuticals buyer in Q2 2016 was Janus Henderson Investors US, an estimated $20.3M added.
- The largest Avadel Pharmaceuticals seller in Q2 2016 was Bank of New York Mellon, an estimated $20.5M sold.
Based on aggregated 13F filings for Q2 2016.